NASDAQ:GWPH - GW Pharmaceuticals PLC- Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$170.10 +16.46 (+10.71 %)
(As of 09/20/2018 04:00 PM ET)
Previous Close$153.64
Today's Range$154.47 - $174.50
52-Week Range$96.42 - $174.50
Volume2.91 million shs
Average Volume410,677 shs
Market Capitalization$4.14 billion
P/E Ratio-23.46
Dividend YieldN/A
GW Pharmaceuticals PLC- logoGW Pharmaceuticals plc, a biopharmaceutical company, engages in discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. The company operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development. Its lead product is Epidiolex, an oral medicine which is in Phase III clinical development for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms. The company also develops and markets Sativex, an oromucosal spray for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates, which are in Phase I and II clinical development for the treatment of glioma, neonatal hypoxic-ischemic encephalopathy, adult epilepsy, and schizophrenia. Further, the company has license and development agreements with Otsuka Pharmaceutical Co. Ltd.; Almirall S.A.; Bayer HealthCare AG; Ipsen Biopharm Ltd; and Neopharm Group. It primarily operates in Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.

Receive GWPH News and Ratings via Email

Sign-up to receive the latest news and ratings for GWPH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations


Debt-to-Equity Ratio0.01
Current Ratio8.67
Quick Ratio8.21


Trailing P/E Ratio-23.46
Forward P/E Ratio-18.67
P/E GrowthN/A

Sales & Book Value

Annual Sales$11 million
Price / Sales429.43
Cash FlowN/A
Price / CashN/A
Book Value$13.92 per share
Price / Book12.22


EPS (Most Recent Fiscal Year)($6.95)
Net Income$-166,900,000.00
Net Margins-1,392.61%
Return on Equity-47.65%
Return on Assets-41.72%


Outstanding Shares27,770,000
Market Cap$4.14 billion

GW Pharmaceuticals PLC- (NASDAQ:GWPH) Frequently Asked Questions

What is GW Pharmaceuticals PLC-'s stock symbol?

GW Pharmaceuticals PLC- trades on the NASDAQ under the ticker symbol "GWPH."

How were GW Pharmaceuticals PLC-'s earnings last quarter?

GW Pharmaceuticals PLC- (NASDAQ:GWPH) released its quarterly earnings data on Tuesday, August, 7th. The biopharmaceutical company reported ($1.26) earnings per share for the quarter, beating analysts' consensus estimates of ($2.40) by $1.14. The biopharmaceutical company earned $3.46 million during the quarter, compared to analyst estimates of $2 million. GW Pharmaceuticals PLC- had a negative net margin of 1,392.61% and a negative return on equity of 47.65%. View GW Pharmaceuticals PLC-'s Earnings History.

When is GW Pharmaceuticals PLC-'s next earnings date?

GW Pharmaceuticals PLC- is scheduled to release their next quarterly earnings announcement on Monday, December, 3rd 2018. View Earnings Estimates for GW Pharmaceuticals PLC-.

What price target have analysts set for GWPH?

7 analysts have issued 12 month target prices for GW Pharmaceuticals PLC-'s shares. Their predictions range from $157.00 to $211.00. On average, they expect GW Pharmaceuticals PLC-'s share price to reach $183.5714 in the next year. This suggests a possible upside of 7.9% from the stock's current price. View Analyst Price Targets for GW Pharmaceuticals PLC-.

What is the consensus analysts' recommendation for GW Pharmaceuticals PLC-?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GW Pharmaceuticals PLC- in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for GW Pharmaceuticals PLC-.

What are Wall Street analysts saying about GW Pharmaceuticals PLC- stock?

Here are some recent quotes from research analysts about GW Pharmaceuticals PLC- stock:
  • 1. According to Zacks Investment Research, "GW Pharmaceuticals plc is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company's lead product, Sativex is used for the treatment of MS symptoms, cancer pain, and neuropathic pain. It operates primarily in the United Kingdom, Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc is based in Salisbury, the United Kingdom. " (8/10/2018)
  • 2. Cantor Fitzgerald analysts commented, "Europe Follows Suit. Following acceptance of the Epidiolex application by the FDA in December, GW announced European acceptance of the application today. In the U.S., the review is expedited, with an advisory panel in 2Q18 and a PDUFA date on June, 27 2018. The company expects a European decision by 1Q19." (2/5/2018)

Who are some of GW Pharmaceuticals PLC-'s key competitors?

Who are GW Pharmaceuticals PLC-'s key executives?

GW Pharmaceuticals PLC-'s management team includes the folowing people:
  • Dr. Geoffrey W. Guy BSc, LMSSA, Dip Pharm Med, MB BS, MRCS Eng, LRCP, Founder & Exec. Chairman (Age 64)
  • Mr. Justin D. Gover, CEO & Exec. Director (Age 47)
  • Mr. Scott M. Giacobello, Chief Financial Officer (Age 48)
  • Mr. Christopher John Tovey BSc, Chief Operating Officer (Age 53)
  • Mr. Douglas B. Snyder, Chief Legal Officer (Age 54)

Has GW Pharmaceuticals PLC- been receiving favorable news coverage?

News headlines about GWPH stock have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm ranks the sentiment of press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. GW Pharmaceuticals PLC- earned a news impact score of 0.18 on Accern's scale. They also gave news stories about the biopharmaceutical company an impact score of 46.57 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next few days. View Recent Headlines for GW Pharmaceuticals PLC-.

Who are GW Pharmaceuticals PLC-'s major shareholders?

GW Pharmaceuticals PLC-'s stock is owned by a number of of institutional and retail investors. Top institutional investors include Scopia Capital Management LP (7.34%), Janus Henderson Group PLC (2.47%), BlackRock Inc. (2.33%), Jennison Associates LLC (1.71%), Bank of America Corp DE (1.66%) and Morgan Stanley (1.36%).

Which major investors are selling GW Pharmaceuticals PLC- stock?

GWPH stock was sold by a variety of institutional investors in the last quarter, including Scopia Capital Management LP, FMR LLC, Point72 Asset Management L.P., Millennium Management LLC, BlackRock Inc., Federated Investors Inc. PA, Jennison Associates LLC and Orbimed Advisors LLC.

Which major investors are buying GW Pharmaceuticals PLC- stock?

GWPH stock was purchased by a variety of institutional investors in the last quarter, including Fred Alger Management Inc., Renaissance Technologies LLC, Baker BROS. Advisors LP, Fiera Capital Corp, Morgan Stanley, Hardman Johnston Global Advisors LLC, Roosevelt Investment Group Inc. and ING Groep NV.

How do I buy shares of GW Pharmaceuticals PLC-?

Shares of GWPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is GW Pharmaceuticals PLC-'s stock price today?

One share of GWPH stock can currently be purchased for approximately $170.10.

How big of a company is GW Pharmaceuticals PLC-?

GW Pharmaceuticals PLC- has a market capitalization of $4.14 billion and generates $11 million in revenue each year. The biopharmaceutical company earns $-166,900,000.00 in net income (profit) each year or ($6.95) on an earnings per share basis. GW Pharmaceuticals PLC- employs 583 workers across the globe.

How can I contact GW Pharmaceuticals PLC-?

GW Pharmaceuticals PLC-'s mailing address is SOVEREIGN HOUSE VISION PARK HISTON, CAMBRIDGE X0, CB24 9BZ. The biopharmaceutical company can be reached via phone at 44-12-2326-6800 or via email at [email protected]

MarketBeat Community Rating for GW Pharmaceuticals PLC- (NASDAQ GWPH)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  461 (Vote Outperform)
Underperform Votes:  228 (Vote Underperform)
Total Votes:  689
MarketBeat's community ratings are surveys of what our community members think about GW Pharmaceuticals PLC- and other stocks. Vote "Outperform" if you believe GWPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GWPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/20/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel